Axsome Therapeutics, Inc

Axsome Therapeutics announced it will report Q2 2026 financial results on August 10, 2026, followed by a management conference call at 8:00 a.m. ET. The company is advancing its CNS disorder treatment portfolio with FDA-approved products including SUNOSI, AUVELITY, and SYMBRAVO, while progressing multiple clinical trials including Phase 3 FOCUS-2...

Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb ano...

Axsome Therapeutics has experienced significant growth with its CNS disorder treatments, including recently approved drugs Auvelity for Alzheimer's agitation and Symbravo for migraines. While the stock has climbed 220% over three years and has strong revenue growth, the article cautions that reaching millionaire status from a single stock investm...

Axsome Therapeutics announced the initiation of the FOCUS-3 Phase 3 trial evaluating solriamfetol for treating ADHD in adolescents aged 12-17. The randomized, double-blind, placebo-controlled trial will enroll approximately 468 patients across multiple centers over 6 weeks, with the primary endpoint measuring changes in ADHD Rating Scale scores.

Hypercharge Networks Corp. announced the grant of 2,630,000 stock options at an exercise price of $0.08 and 1,115,464 deferred share units to directors, officers, employees, and consultants. The company also announced it was named co-winner of the Canada Growth Cup and grew its total charging ports by over 45% through the acquisition of Eddie fro...